Funding for this research was provided by:
Agency for Healthcare Research and Quality (R18-HS020002)
National Institute of Allergy and Infectious Diseases (K01-AI137317, K24-AI080942, K01-AI103028)
Centers for Disease Control and Prevention (FOA#CK000163)
Antibacterial Resistance Leadership Group (5 UM 1AI104681-05)
Received: 20 June 2018
Accepted: 11 February 2019
First Online: 14 February 2019
Ethics approval and consent to participate
: This study was approved by the University of Pennsylvania’s Institutional Review Board (Protocol 812302). Verbal informed consent was obtained from study participants, rather than written consent, because consent was obtained at the time of a follow-up phone call after the patient’s clinical visit for the UTI. Written informed consent was not feasible since the patients were no longer in the clinic/hospital when they were enrolled in the study.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.